Eli Lilly and Company $LLY Stock Holdings Raised by Verdence Capital Advisors LLC

Verdence Capital Advisors LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 0.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 8,599 shares of the company’s stock after purchasing an additional 17 shares during the period. Verdence Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $6,703,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Delaney Dennis R increased its position in shares of Eli Lilly and Company by 36.7% in the 2nd quarter. Delaney Dennis R now owns 1,878 shares of the company’s stock worth $1,464,000 after purchasing an additional 504 shares during the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Eli Lilly and Company by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 67,913 shares of the company’s stock worth $52,940,000 after purchasing an additional 200 shares during the last quarter. RoundAngle Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 4.8% in the 2nd quarter. RoundAngle Advisors LLC now owns 2,109 shares of the company’s stock valued at $1,644,000 after buying an additional 97 shares during the period. Concord Asset Management LLC VA boosted its holdings in shares of Eli Lilly and Company by 20.2% in the 2nd quarter. Concord Asset Management LLC VA now owns 3,652 shares of the company’s stock valued at $2,847,000 after buying an additional 614 shares during the period. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 19.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company’s stock valued at $109,291,000 after buying an additional 22,410 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 in the last ninety days. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Down 1.8%

LLY stock opened at $818.60 on Tuesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market cap of $774.77 billion, a price-to-earnings ratio of 53.50, a PEG ratio of 1.18 and a beta of 0.47. The company has a 50 day moving average of $743.43 and a two-hundred day moving average of $765.54.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter last year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on LLY shares. Morgan Stanley decreased their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday, October 3rd. Leerink Partners restated a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Cantor Fitzgerald set a $925.00 target price on shares of Eli Lilly and Company and gave the stock an “overweight” rating in a research report on Thursday. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Finally, Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research report on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $948.06.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.